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Abstract
The postulated almost unlimited potential of transplanted
hematopoietic stem cells (HSCs) to transdifferentiate into
cell types that do not belong to the hematopoietic sys-
tem denotes a complete paradigm shift of the hierarchi-
cal hemopoietic tree. In several studies during the last
few years, donor cells have been identified in almost all
recipient tissues after allogeneic HSC transplantation
(HSCT), supporting the theory that any failing organ could
be accessible to regenerative cell therapy. However, the
putative potential ability of the stem cells to cross beyond
lineage barriers has been questioned by other studies
which suggest that hematopoietic cells might fuse with
non-hematopoietic cells and mimic the appearance of
transdifferentiation. Proof that HSCs have preserved the
capacity to transdifferentiate into other cell types remains
to be demonstrated. In this review, we focus mainly on
clinical studies addressing plasticity in humans who
underwent allogeneic HSCT. We summarize the pub-
lished data on non-hematopoietic chimerism, donor cell
contribution to tissue repair, the controversies related to
the methods used to detect donor-derived non-hema-
topoietic cells and the functional impact of this phenom-
enon in diverse specific target tissues and organs.
Keywords: fusion; hematopoietic stem cell
transplantation; humans; microchimerism; organ repair;
plasticity; transdifferentiation.
Introduction
The hematopoietic stem cell (HSC) is defined as a cell
with extensive self-renewal, proliferation capacity, as well
as the capacity to differentiate into progenitors of all
blood cells: erythrocytes, granulocytes, monocytes,
platelets, and all subtypes of lymphocytes. A single HSC
has the ability to establish long-term hematopoiesis. This
ability of long-term repopulation has been widely used
for nearly four decades for hematopoietic stem cell trans-
plantation (HSCT). After successful HSCT, a normal poly-
clonal hematopoiesis is reconstituted in the recipient.
There are an increasing number of studies providing
evidence that regenerative cell-based therapies can lead
to functional organ repair. As a result, there is a need for
cells of the stem cell type to be able to be differentiated
into mature organ-specific cells with complete functional
capacity. Alternatively, human embryonic stem cells are
pluripotential cells with the potential to differentiate into
any cell type in the presence of adequate stimulating fac-
tors and suitable environments. So far, the clinical use of
embryonic stem cells for regenerative medicine is ham-
pered by a number of technical, political and ethical bar-
riers. Consequently, there is a desire for other types of
human stem cells capable of differentiating and prolifer-
ating into defined mature cells. HSCs appear to be an
ideal candidate, as they have a great capacity to prolif-
erate and are easily obtained. Proof that HSCs have pre-
served the capacity to transdifferentiate into other cell
types remains to be demonstrated.
Recently, a series of exciting reports has placed mar-
row-derived stem cells as the first candidate for such
use. In vitro (Reyes et al., 2001; Collas, 2003) and animal
studies (Gussoni et al., 1999; Brazelton et al., 2000; Ali-
son et al., 2001, 2003; Krause et al., 2001; Akiyama et
al., 2002; LaBarge and Blau, 2002; Masuya et al., 2003;
Doyonnas et al., 2004; Palermo et al., 2005) postulated
the nearly unlimited potential of stem cells. Results from
studies performed in mice following a rigorous study
design provided the reference and the context for further
investigation in humans. Subsequently, many studies
performed in humans have identified donor cells in
almost all recipient tissues, supporting the theory that
any failing organ could be accessible to regenerative cell
therapy (Figure 1) (Alison et al., 2000; Korbling et al.,
2002; Tran et al., 2003; Cogle et al., 2004; Spyridonidis
et al., 2004).
The putative potential ability of stem cells to cross
beyond lineage barriers (Anderson et al., 2001; Blau et
al., 2001) has been denominated ‘plasticity’ and it refers
specifically to transdifferentiation. However, this concept
of plasticity has been questioned. Some studies did sug-
gest that stem cells might fuse with other cells and mimic
the appearance of differentiation (Vassilopoulos et al.,
2003; Wang et al., 2003). Likewise, other studies postu-
lated the presence of fetomaternal microchimerism as
the explanation for this finding (Evans et al., 1999; Reed
et al., 2007).
The disparity of results, the difference in the methods
used to investigate transdifferentiation or plasticity, and
thus also the difficulties in reproducibility, converted the
initial excitement into a more skeptical position. Many
investigators called for caution in the interpretation of the
results of studies. Today, deep uncertainty remains
regarding the plasticity of HSCs. The argument in favor
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Figure 1 Potential contribution of bone marrow-derived cells to organ repair.
Terese Winslow, reproduced with permission.
of plasticity of HSCs is supported by the plethora of
publications and the extensive debate in the community
as reflected in the media.
In this review, we focus mainly on clinical studies
addressing plasticity in humans who underwent alloge-
neic HSCT. Clinical allogeneic HSCT provides a unique
opportunity to assess the contribution of transplanted
healthy allogeneic donor cells for organ repair. Because
most patients are pretreated with intensive chemo- and
radiotherapy, the so-called conditioning, the recipient
organs are consequently in high need of repair. If donor
cells could contribute to such regenerative organ repair
and thereby should be confirmed. We summarize the
published evidence of donor cell contribution to tissue
repair, the methods used for its detection and the func-
tional impact in different specific target organs. Postulat-
ed mechanisms of the donor-derived stem cells in organ
repair are further addressed.
Mechanisms for non-hematopoietic mixed
chimerism after allogeneic HSCT
Mixed chimerism is a term used in transplantation med-
icine to define a cellular phenomenon, where the recipi-
ent of a transplant has cells of his own as well as from
the organ donor. In allogeneic HSCT, a mixed chimerism
is usually defined as a situation in which the hematopoi-
etic cells belong in part to the recipient and, for the other
part, to the donor (Figure 2). The term non-hematopoietic
mixed chimerism can be used post-allogeneic HSCT,
where non-hematopoietic cells in the recipient can be of
both recipient and donor origin. There are several pos-
sible mechanisms that could lead to a non-hematopoietic
mixed chimerism; these are plasticity, transdifferentiation,
fusion and fetomaternal microchimerism.
Plasticity and transdifferentiation
The ability of the HSCs to transdifferentiate into cell types
that do not belong to the hematopoietic system denotes
a complete paradigm shift of the hierarchical hemato-
poietic tree. The differentiation of HSCs into muscle can
be acceptable, considering that blood cells and muscle
cells belong to the same germ layer, the mesoderm
(Peault et al., 2002). This process might even be bidirec-
tional. Crossing barriers within the same germ layer is
referred to as plasticity. In contrast, HSCs differentiating
into intestinal epithelial cells would represent crossing of
the embryo germ layer barrier (mesoderm to endoderm)
and is referred to as a transdifferentiation phenomenon
(Figure 3). Transdifferentiation in vitro involves a signal
which reprograms the genes expression profile in the
nucleus (Reyes et al., 2001; Tada et al., 2001; Collas,
2003). In this process, regulatory factors are actively tak-
en up by the nucleus, inciting the cells to express mol-
ecules and functions by downregulating the expressed
genes in the original cells.
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Figure 2 Chimerism analysis after allogeneic hematopoietic stem cell transplantation (HSCT).
Chimerism of peripheral blood by PCR-based DNA amplification of nine different short tandem repeat (STR) loci and the Amelogenin
locus, which allows discriminating the X and Y chromosomes. For PCR amplification of the STR, the AmpFlProfilerPCRAmplification
Kit (PE Applied Biosystems, Foster City, USA) was used. PCR products were separated by capillary electrophoresis on the ABI Prism
310 Genetic Analyzer (PE Applied Biosystems) and fragment sizes were analyzed with the GeneScan software. Informative peaks,
i.e., peaks which are different between recipient and donor, were used for calculation of the donor contribution. The peak integral
served for the relative quantification of the product.
Figure 3 Schematic representation of adult mammals’ embryonic development (black arrows).
Plasticity within and across germ layer lines, hypothetical pathway (red and blue arrows).
The molecular basis of transdifferentiation, dedifferen-
tiation and stem cell plasticity may be explained by aber-
rant processes during cell differentiation. Hence, at some
stages of cell differentiation or metabolic switch, cells
undergo profound changes in gene expression. These
events are associated with complex modifications of
chromosomal components and nuclear structures, going
from simple covalent modification of DNA and chromatin
up to topological reorganization of chromosomes and
genes in the nucleus. Epigenomic levels of gene regula-
tion usually contribute to the stability and heritability of
transcription programs. When damage of the epigenomic
components occurs, a determined cellular program can
result to skewed development. These aberrant processes
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Figure 4 Cell fusion schematic.
(A) Fusion of a diploid blood cell and tetraploid hepatocyte, resulting in a binucleated hybrid, which then becomes a hexaploid fusion
hepatocyte. (B) Fusion of diploid blood cell and diploid hepatocyte to form a tetraploid fusion hepatocyte. This cell can undergo a
reduction division and become diploid again. (C) FISH analysis of a hexaploid fusion hepatocyte that has two Y (pink) and four X
(green) chromosomes. Adapted from Grompe (2003) (Thieme, reproduced with permission).
can be detected by gene expression profiles, as well as
by analysis of epigenetic modification of DNA and his-
tone proteins of the involved cells (Lanzuolo and Orlando,
2007; Li et al., 2007; Rizzino, 2007). In mice and in
humans, mechanisms regulating self-renewal and cell
fate decisions may be approached by global gene
expression profiles of HSCs and cells at later stages of
the hematopoietic hierarchy. Indeed, murine and human
HSCs share a number of expressed gene products,
which define key conserved regulatory pathways in this
developmental system. Moreover, in the mouse, part of
the genetic program used by HSCs is shared with embry-
onic and neural stem cells. This overlapping gene prod-
uct represents a molecular signature of stem cells
(Ivanova et al., 2002; Ramalho-Santos et al., 2002).
Regarding the terminology there is no real consensus
about how to denominate this phenomenon. Several
authors do not differentiate plasticity from transdifferen-
tiation and use both terms interchangeably, whereas oth-
er authors prefer to omit the use of the term plasticity to
minimize confusion and use transdifferentiation to make
the distinction. The term plasticity has been widely
referred to as the capacity of adult stem cells to cross
lineage barriers.
Methodological limitation has been pointed out as the
most difficult aspect for the interpretation of the results
of plasticity and transdifferentiation. The following criteria
should be fulfilled to demonstrate these phenomenon in
vivo (Anderson et al., 2001): the donor population should
be prospectively isolated and transplanted without inter-
vening culture manipulations, the transplanted stem cells
should give rise to robust and sustained regeneration of
the target tissues; the converted cells need to have not
only the anticipated anatomical and molecular pheno-
type, but also the functional characteristics. In addition,
transdifferentiated stem cells should have normal chro-
mosome contents. Finally, the presence of contaminated
cells should always be considered as confounding fac-
tors and should be systematically ruled out.
Fusion
Cell fusion could be a mechanism that explains part of
the results of transdifferentiation of HSCs into liver cells
(Figure 4) (Grompe, 2003), cardiomyocytes and neurons.
This mechanism seems to be, in part, responsible for
bone marrow-derived stem cell repair of damaged tissue
(Medvinsky and Smith, 2003).
In a mice model, Alvarez-Dolado and colleagues, using
a simple method based on Cre/lox recombination (a
technique extensively used to conditionally turn on or off
gene expression in specific cell types or tissues) to
detect cell fusion events, demonstrated that bone mar-
row-derived cells fuse spontaneously with neural progen-
itors in vitro. Furthermore, bone marrow-derived cells
fuse in vivo with hepatocytes in liver, Purkinje neurons in
the brain and cardiac muscle in the heart, resulting in the
formation of multinucleated cells. No evidence of trans-
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differentiation without cell fusion has been observed in
these tissues (Alvarez-Dolado et al., 2003). Terada et al.
(2002) demonstrated that mice bone marrow cells can
fuse spontaneously with embryonic stem cells in vitro
cultures that contain interleukin-3. Additionally, other
studies reported that spontaneously fused bone marrow
cells can subsequently adopt the phenotype of the recip-
ient cells, a phenomena which, without detailed genetic
analysis, might be interpreted as ‘dedifferentiation’ or
transdifferentiation (Ying et al., 2002).
Fetomaternal microchimerism
Microchimerism is defined as the presence of a small
number of cells genetically distinct from those of the
host. The most common form is fetomaternal microchi-
merism, where cells from a fetus are found in the mother.
Fetal cells have been documented to persist in maternal
circulation and tissues for as long as 38 years (Bianchi
et al., 1996; Evans et al., 1999). Stem cells or tissues
obtained from a woman who has been pregnant are likely
to contain cells of her fetuses. This chimeric cell popu-
lation may have different biological properties as com-
pared to adult stem cells or organ cells obtained from a
nulliparous woman or from a man (Bianchi and Fisk,
2007). Fetomaternal microchimerism can also develop
during abortion. Using polymerase chain reaction to
measure Y-chromosomal sequences, up to 500 000
nucleated fetal cells enter a woman’s circulation following
routine surgical abortion (Bianchi et al., 2001). For plas-
ticity evaluation, many of the studies used Y-fluorescence
in situ hybridization (Y-FISH) as a method to track donor
HSC-derived cells in sex-mismatch transplantation. In
females with previous pregnancies or abortions with a
male fetus, the potential presence of fetomaternal micro-
chimerism could be a confounding factor in positive
results. Indeed, in a carefully conducted single-center
study, data did fit with this hypothesis demonstrating a
potential impact on clinical HSCT. Siblings born after the
recipients should have fetomaternal and transmaternal
sibling cell trafficking and tolerization of the donor. First-
born recipients should therefore experience less acute
graft versus host disease, incidence of relapses and
transplant related mortality (Bucher et al., 2007) More-
over, microchimerism has also been demonstrated after
blood transfusions in severely immunocompromised
patients who suffered trauma (Reed et al., 2007).
Evidence of HSC contribution to tissue repair
HSC differentiation in the central nervous system
Bone marrow cells have been reported to differentiate
into neurons and astrocytes when transplanted into nor-
mal and ischemic brain (Bjornson et al., 1999; Eglitis et
al., 1999; Woodbury et al., 2000). After intravenous appli-
cation of bone marrow fraction into terminally X-irradi-
ated rats, cells with neuronal phenotypes derived from
the injected bone marrow can be found in the brain
(Brazelton et al., 2000; Mezey et al., 2000). In humans,
Cogle et al. (2004) demonstrated that HSCs can trans-
differentiate into neurons, astrocytes and microglia. They
examined autopsy brain specimens from three sex-mis-
matched female bone marrow transplantation patients, a
female control and a male control. They performed
immunohistochemistry, FISH and tissue analysis to look
for multilineage, donor-derived neurogenesis. In all three
patients, a Y chromosome was present in the hippocam-
pal cells up to 6 years post-transplant. Transgender neu-
rons accounted for 1% of all neurons. The fact that only
one X chromosome was present excluded the hypothesis
of cell fusion as an explanation for this phenomenon.
Moreover, transgender astrocytes and microglia made up
1–2% of all glial cells (Cogle et al., 2004).
Crain et al. (2005) examined paraffin sections from
female patients who had received bone marrow trans-
plants from male donors. Y-chromosomes were labeled
using autoradiography and FISH. Neurons and astro-
cytes were identified histologically and immunohisto-
chemically in neocortex, hippocampus, striatum and
cerebellum. However, most Y-chromosome labeled cells
in gray and white matter appeared to be glia. The female
patients in this study had received either bone marrow
or stem cell (CD34q-enriched) transplants from their
brother. Genotyping studies of one patient, her brother,
and her son ruled out the possibility of fetomaternal
microchimerism. Overall, the numbers of labeled cells
(including neurons) were approximately 10-fold lower
than in rodent studies (2–5/10 000 vs. 50/10 000) (Bra-
zelton et al., 2000; Mezey et al., 2000). Furthermore, 3
out of 4 required criteria to demonstrate plasticity of adult
stem cells were fulfilled. The positive findings could not
be explained by cell fusion.
Other groups have shown that Purkinje neurons from
the cerebellum can fuse with bone marrow-derived cells
in both mouse and human beings (Alvarez-Dolado et al.,
2003; Weimann et al., 2003a,b). Weimann et al. (2003a)
showed, in cerebella sections screened for Y-chromo-
somes, that the total frequency of male bone marrow
contribution to female Purkinje cells approximated 0.1%.
Despite the fact that Purkinje neurons are no longer gen-
erated after birth, in humans, bone marrow cells could
contribute to the formation of new neurons in adults,
meaning in fact that two mechanisms of neuronal devel-
opment have to be envisioned. Cells from bone marrow
could fuse with damaged neuronal cells, providing them
with an undamaged nucleus. Alternatively, cells of donors
could undergo a change in their cell fate and replenish
damaged tissues by converting their phenotype into the
cell type needed in the tissue to which they migrated.
HSC to skin and endothelium
Experimentally, it has been demonstrated that bone mar-
row-derived cells contribute to epithelial engraftment
during wound healing (Borue et al., 2004). Murata et al.
(2007) evaluated 18 female patients who underwent
HSCT from a male donor, in whom a skin rash led to a
skin biopsy. Acute Graf-versus-Host Disease (GvHD) was
confirmed in 13 of them. Donor-derived keratinocytes,
characterized as CD45-, AE1/AE3q and XY cells, were
found in 12 patients with an average of 5.5% (range
1.6–7.8%). Donor-derived endothelial cells, character-
ized as CD31q, CD45- and XY cells were found in skin
biopsies of 13 patients (mean 4.3%; range 2.2–9.4%).
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These data were in accordance with a previously pub-
lished study (Jiang et al., 2004), in which a mean of 2%
donor-derived endothelial cells were reported in the skin
and gut of human transplant recipients. In this last study,
3 out of 12 patients had GvHD and all three showed
donor-derived endothelial cells. In both studies, there
was a close association between chimeric cells and
pathologically proven acute GvHD, suggesting the con-
tribution of donor-derived cells in endothelial repair of
GvHD-induced lesions.
Human tissue samples from the aorta and peripheral
arteries were obtained at autopsy in the case of a patient
who underwent peripheral HSCT for acute radiation syn-
drome. Endothelial cells, characterized by von Willebrand
factor immunostaining, were isolated and subjected to
FISH analysis using X- and Y-chromosome-specific
probes to examine neoendothelialization by donor cells.
In the aorta, almost 25% of all endothelial cells were
replaced by donor-origin endothelial cells. In the periph-
eral arteries a similar, less extensive phenomenon was
observed (Suzuki et al., 2003).
HSC to hair follicles and fingernails
Transient hair injury and as a result alopecia is evident in
most patients after HSCT, mainly when intensive condi-
tioning is applied. We assessed chimerism quantifica-
tions on DNA extracted from hair follicles in a large cohort
of 115 patients after HSCT. Despite being an organ with
high need for repair, all hair follicles showed 100% recip-
ient alleles and were therefore fully of recipient type
(Rovo et al., 2005; Seifert et al., 2005). Recently, these
results were confirmed by Hong et al. Using the same
short tandem repeat (STR) method, they established that
hair follicles were 100% recipient type in all 29 evaluated
patients and suggested that after successful allogeneic
HSCT, the hair follicle is a reliable source of the recipient’s
origin when pre-transplant DNA fingerprinting from donor
and recipient is not available (Hong et al., 2007).
Hair and nail have similar biologic features; they share
the same origin from ectoderm and have a lifelong, con-
tinuous regeneration. We would therefore expect similar
results in chimerism performed from fingernails com-
pared to hair follicle after allogeneic HSCT. However, a
recent publication applying the same STR method of
detection in recipients’ fingernails showed opposite
results. In 9 out of 21 recipients, coexistence of donor
pattern in a range from 8.9% to 72.9% was identified.
GvHD was not associated with this finding. The authors
interpreted this result as stable donor contribution,
despite the fact that they were unable to track individual
cells with this method (Imanishi et al., 2007).
HSC to liver
Theise and colleagues showed that 4–43% of the hepa-
tocytes and 4–38% of the cholangiocytes in liver biopsy
and in autopsy material from two female patients after
HSCT were of donor bone marrow cell origin (Theise et
al., 2000). Shortly afterward, Korbling and colleagues
reported that stem cells in mobilized peripheral blood
and marrow showed plasticity in vivo. They found that
2–7% of hepatocytes and epithelial cells of skin and gut
were of donor origin 13–867 days after transplantation
(Korbling et al., 2002).
HSC to buccal mucosa
STRs are markers which are currently used in forensic
medicine to demonstrate diversity in tissue derived from
different individuals. The same method is now widely
applied to demonstrate hematopoietic chimerism after
allogeneic HSCT. This method is robust, reproducible,
provides good sensitivity, and is not dependent on a sex-
mismatch between recipient and donor (Thiede et al.,
1999, 2001, 2004; Thiede, 2004). The oral mucosa rep-
resents an attractive source of suitable material for DNA-
based assessment of hematopoietic chimerism after
HSCT, because after successful HSCT, buccal mucosa
is supposed to be of recipient, and hematopoietic cells
from donor origin. This is a particularly useful method
when the DNA profile from the donor is not available for
chimerism evaluation. Cheek mucosa collected samples
using both mouthwashes as well as buccal swab show
a mixed chimerism with 74% (range 16–95%) and 21%
(5–63%) of donor type, respectively. These results are
due to blood cell contamination (Endler et al., 1999;
Thiede et al., 2000). Beyond these results on buccal
mucosa, Tran and colleagues (2003) evaluated whether
bone marrow donor cells could colonize an epithelial tis-
sue and transdifferentiate there without fusion. They
tracked donor-derived buccal mucosa cells using an
anticytokeratin 13 antibody to detect mucosal cells and
a FISH method to identify male donor origin of buccal
epithelial cells in cheek scrapings obtained from female
patients. In total, there were five female patients who had
received either bone marrow or mobilized peripheral
blood progenitor cells (enriched in CD34qcells) for HSCT
from male donors 4–6 years before. All female recipients
had Y chromosome positive buccal cells (0.8–12.7%)
without evidence of cell fusion. Because in more than
9700 cells studied, only one XXXY-positive cell (0.01%)
and one XXY cell (0.01%) was detected, both of them
could be the result of XY cell fusion with an XX cell.
HSC to gastrointestinal mucosa
Meignin and colleagues performed gastrointestinal bi-
opsy in six female patients with acute GvHD within
13–33 days after allogeneic HSCT (Meignin et al., 2004).
Using stringent criteria, no donor-derived epithelial cells
could be found. Their results differ from previously pub-
lished data on the human digestive tract after HSCT,
where epithelial cells of donor origin were regularly found
at a low rate (Brittan et al., 2002; Korbling et al., 2002;
Okamoto et al., 2002). These earlier studies were per-
formed in sex-mismatched transplantation but with dif-
ferent technical conditions used for tissue preparation.
Meignin et al. (2004) used the XY FISH method, which
allows for the elimination of most non-specific signals,
large-spectrum fluorescence. They also combined FISH
and immunostaining results on the same tissue section
to avoid serial consecutive sections, and in the same way
localization bias.
Spyridonidis and colleagues (Spyridonidis et al., 2004)
demonstrated with a very comprehensive and rigorous
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method that chimerism of colon epithelium is a real phe-
nomenon occurring constantly after human HSCT. Colon
snap-frozen biopsies were performed in eight female
patients with clinical signs of gastrointestinal GvHD who
underwent a sex-mismatched allogeneic HSCT. Using
confocal microscopy and 3D analysis on single sections
of biopsies, and using triple staining with donor-specific
(Y), epithelial-specific (cytokeratin) and hematopoietic-
specific (CD45) markers, they detected Yq/cytokeratinq/
CD45-, donor-derived epithelial cells in all patients. The
mean of donor-derived cells was 0.18% of the overall
colon epithelial cells, with higher numbers found in the
sections with histologically documented tissue damage
(mean 0.22%; six patients). They ruled out fusion as the
underlying mechanism, combining cytokeratin staining
with YX-FISH quantitative method. Moreover, the major-
ity of the intraepithelial chimeric events found were due
to donor type Yq/CD45q intraepithelial lymphocytes
which were in close contact with epithelial tissue. The
authors warn about the risk of falsely interpreting these
donor lymphocytes as donor-derived epithelial cells if the
3D structure of the tissue is not considered in combina-
tion with the hematopoietic markers.
HSC to endometrium
The endometrium is a dynamic, cyclically regenerating
tissue, and therefore represents a unique model of phys-
iological angiogenesis in adults. Mints et al. (2007) eval-
uated whether newly formed male endothelial cells in
mice and humans could be detected in the endometrial
blood vessels of female recipients after HSCT from a
male donor. They performed endometrial biopsies after
cesarean section in a patient treated previously with non-
myeloablative allogeneic HSCT, and in two controls.
Endothelial cells were detected by immunohistochemis-
try using CD34 and VEGFR2 antibodies, and donor cell
origin by FISH analysis. Chimerism was analyzed using
real-time PCR. The same experiment was also performed
in an animal model. They found that at the time of the
cesarean section of the transplanted female patient, an
average of 14% of the endometrial endothelial cells were
donor-derived. In a biopsy repeated 1 year later, the
donor-derived endothelial cells were still 10%. In con-
trast, none of two non-transplanted females demonstrat-
ed a sex-mismatch in endometria at cesarean section. In
samples from female mice, harvested 40 days after
HSCT, a 6% average of donor-derived endothelial cells
was detected (Mints et al., 2007).
HSC to lung
After lung injury and damage to the alveolar epithelium,
the underlying basement membranes become exposed.
Proliferation of type II pneumocytes and their differenti-
ation into type I pneumocytes have been considered to
be the mechanism by which repopulation of the alveolar
epithelium occurs. Different groups showed that, as in
animal models, the epithelium of the adult human lung
has the capacity to renew itself, using cell recruitment
from extrinsic sources. Several studies evaluated lung
specimens from surgical resection or autopsy samples
from female patients who had received an HSCT from a
male donor. Using a combination of immunochemistry
and FISH technique, the presence of cells from HSC
donor origin has been shown by all groups. However, the
occurrence of fusion was not systematically ruled out
(Suratt et al., 2003; Mattsson et al., 2004; Albera et al.,
2005; Loebinger and Janes, 2007).
HSC to heart and muscle
Attempts to repair myocardial infarcts by transplanting
cardiomyocytes or skeletal myoblasts have failed to
reconstitute healthy myocardium and coronary vessels
integrated structurally and functionally with the remaining
viable portion of the ventricular wall. Orlic and colleagues
demonstrated in a mouse model that bone marrow cells
injected in the border zone of acute infarcts Lin2 c-
kitPOS from syngeneic animals differentiated into myo-
cytes and vascular structures, ameliorating the function
of the infarcted heart (Orlic et al., 2001). In humans, sev-
eral studies suggest improvement in cardiac function
when autologous bone marrow or peripheral stem cell is
injected directly into damaged myocardium. In these
studies, it was not possible to assess whether the
improved outcomes did result from generation of HSC-
derived myocytes or were due to ancillary effects (Stamm
et al., 2003, 2004; Tse et al., 2003; Heil et al., 2004;
Mathur and Martin, 2004; Wollert et al., 2004; Drexler et
al., 2006; Meyer et al., 2006; Griesel et al., 2007; Sohn
et al., 2007). Some authors suggested that HSC might
promote vascular growth by their paracrine effects and
not by incorporation into the wall of growing vessels.
There are almost no data on the contribution of alloge-
neic HSCT to myocardial repair in humans.
Growth and repair of skeletal muscle is normally medi-
ated by the satellite cells that surround muscle fibers.
During muscle regeneration, however, the number of
myogenic precursors exceeds that of resident satellite
cells, implying migration or recruitment of undifferentia-
ted progenitors from other sources. In animal models, the
injection of bone marrow into the circulation contributes
to muscle enhancement in response to increased muscle
activity. These results indicate that bone marrow-derived
cells contribute to myofibers in response to physiologic
stress encountered by healthy organisms throughout life
(Ferrari et al., 1998; Palermo et al., 2005). In humans,
Gussoni et al. (2002) reported on the examination of
muscle biopsies from a patient who received bone mar-
row transplantation at 1 year of age for X-linked severe
combined immune deficiency and who was diagnosed
with Duchenne muscular dystrophy at the age of
12 years. Analysis of muscle biopsies, performed at the
time the Duchenne muscular dystrophy was already
diagnosed, revealed the presence of donor nuclei within
a small number of muscle myofibers (0.5–0.9%), showing
the ability of exogenous human bone marrow cells to
fuse into skeletal muscle and persist up to 13 years after
HSCT (Gussoni et al., 2002).
Cancer originating from donor HSC
HSCT is now successfully utilized in the treatment of
malignant and non-malignant diseases resulting in a
growing cohort of long-term survivors. The development
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of subsequent malignant neoplasms is one of the major
long-term adverse complications observed in these
patients. Usually, these secondary solid cancers are of
recipient type. However, the conjecture about the cell ori-
gin of the non-hematopoietic tissues after HSCT has led
to a closely related theory that cancer could also be
donor-derived. So far, the evidence of this hypothesis is
extremely scarce and only further systematic searches
for donor-derived stem cells in the newly diagnosed solid
tumor in long-term survivors after HSCT will shed some
light on this controversial theory (Houghton et al., 2004;
Alison et al., 2006; Arai et al., 2006; Avital et al., 2007;
Soldini et al., 2008).
Are the current results inaccurate by
over-interpretation? Evaluation of the methods
used to detect non-hematopoietic mixed
chimerism
Most of the controversies on plasticity are related to the
methods used to detect donor-derived non-hematopoi-
etic cells in various tissues and organs. To demonstrate
HSC plasticity or transdifferentiation, all the proposed cri-
teria have to be fulfilled (Anderson et al., 2001). The rel-
evant cell type must be unequivocally identified using
immunohistochemistry, immunofluorescence and func-
tional assay. A combination of more accurate methods,
including 3D to track cells using a more specific
approach, should be systematically applied (Spyridonidis
et al., 2004; Murata et al., 2007). To exclude cell fusion
(Alison et al., 2004), the karyotype of newly generated
cells needs to be detected using, e.g., the method of
FISH which allows counting of the number of chromo-
somes and tags specific chromosomes with unique fluo-
rescent dyes (Figure 4C). Karyotyping with FISH distin-
guishes between cellular transdifferentiation (diploid,
donor genotype) and cell fusion (tetraploid or greater,
mixed donor, and recipient genotypes). The proof for
evaluating whether cells belonging to the donor or the
recipient is usually based on genetic differences. In most
cases, an in situ technique is used to detect the sex dif-
ference. Unfortunately, in humans, only patients who
have a donor from the opposite sex will be suitable for
this analysis.
The DNA-based STR method, used to reveal donor-
derived HSC chimerism, has an evident limitation in the
case of mixed non-hematopoietic chimerism. The result
refers to the presence of donor type cells but does not
provide further information regarding cell identity. In such
a case, the interpretation should be posited with extreme
caution. The most usual pitfall is due to the contamina-
tion of the material by hematopoietic donor cells, such
as lymphocytes, leading to a result that can be misinter-
preted as donor-derived cell plasticity. Indeed, in our
study on male spermatogenesis after HSCT (Rovo et al.,
2006), we were looking for chimerism in sperm samples
when spermatozoa was detected in the microscopic
fresh analysis. STR analysis was performed from six fro-
zen sperm samples. The results showed a mixed chi-
merism in all patients with a percentage of donor
contribution between 20% and 40% (data not published).
These provocative results were highly questionable. Con-
sequently, we systematically reviewed the cytological
protocols of the sperm samples provided by the andro-
logy laboratory. A very low rate of lymphocyte contami-
nation has been systematically described, explaining the
outcome. Positive results published recently, in which
STR was applied as a detection method for mixed non-
hematopoietic chimerism in fingernail, revived the
debate. The authors depicted between 8.9% and 72.9%
donor type DNA obtained from fingernails, and conclud-
ed that this represents a stable contribution of HSC
donor cells to fingernail production after HSCT. They
rejected the possibility of contamination by donor type
hematopoietic cells, even though they used an indirect
method to demonstrate absence of lymphocytes in fin-
gernails in another group of patients (Imanishi et al.,
2007).
Where are we, where are we going?
Based on numerous studies in allogeneic HSCT (Table
1), there is now data to support the concept that donor-
derived cells can be found in various tissues and organs
of the recipients after successful transplantation. In some
cases, it seems that plasticity and transdifferentiation
plays a determinant role. However, other phenomena,
such as cell fusion, can lead to conflicting results. Over
the last few years, we have learnt much about technical
drawbacks leading to misinterpretation of the results. We
know now which stringent criteria have to be applied to
prove cell plasticity. There is evidence that the low fre-
quency of HSC-derived non-hematopoietic cells showed
in many organs seems to be too low to be of therapeutic
relevance. Overall, plasticity after allogeneic HSCT
seems to be an erratic event, without a specific pattern
for contributing factors. Moreover, there are no hints on
how to influence the degree of chimerism on organ repair,
and so far, long-term repeated follow-up studies are lack-
ing. We can conclude that unmanipulated HSCs are
therefore unlikely to provide organ repair beyond hema-
topoiesis either from adult bone marrow or mobilized
peripheral stem cells. Whether other organ specific stem
cell progenitors circulating in blood constitute a backup
to maintain homeostasis in self-renewal and a repair of
different tissues or not should be addressed (Hennessy
et al., 2004). This review permits the conclusion that
there is a need for systematic cross-sectional and lon-
gitudinal observational studies, which should lead to
defining factors associated with the degree of chimerism.
Different potential scenarios can be drawn for the future:
(1) we will be able to identify and influence factors asso-
ciated with chimerism, and hence we will find tools to
induce chimerism or influence homing; (2) there will be a
necessity for in vitro manipulation of HSCs prior to appli-
cation to induce target-specific orientation or homing;
and finally, (3) HSCT would no longer be needed, as the
possibility of reprogramming cells will obviate the need
for non-specific stem cell induced organ repair (Takaha-
shi et al., 2007).
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